Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer

Starting soon · Phase 2

Conditions studied: Lung, Radiotherapy

In brief

This study is a multicenter, prospective investigation aiming to evaluate the efficacy and safety of low-dose radiotherapy (15Gy/1.5 Gy bid × 10 fractions) combined with 4-6 cycles of systemic chemotherapy concurrently with Adebrelimab, followed by Adebrelimab maintenance therapy for up to two years, in subjects with extensive-stage small cell lung cancer (ES-SCLC). Additionally, immunohistochemical detection of the expression levels of four key transcriptional proteins-YAP1, NEUROD1, ASCL1, and POU2F3-will be performed to guide the molecular subtyping of SCLC. Based on these findings, we will explore the differential therapeutic outcomes of this regimen across distinct molecular subtypes (A/N/P/Y/I/AN/QN), with the goal of identifying the subject population most likely to benefit from this treatment modality, thereby optimizing clinical decision-making.

Key facts

Study ID

NCT07583550

Run by

Jiangmen Central Hospital

People needed

43

Starts

2026-07-21

Expected to finish

2028-01-01

Last updated by the study team

2026-07-22

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years and ≤75 years;
• Histologically or cytologically confirmed SCLC;
• No malignant pleural effusion or pericardial effusion;
• No prior history of thoracic radiotherapy or thoracic surgery;
• No prior systemic anti-tumor therapy;
• ECOG performance status 0-2, with a life expectancy of ≥12 weeks;
• At least one measurable lesion per RECIST 1.1 criteria;
• No history of interstitial pneumonia;
• No history of immune-related pneumonitis;
• No history of autoimmune diseases;
• No history of significant active pulmonary infection;
• No use of corticosteroid therapy within 14 days prior to enrollment;
• No Grade ≥3 hematologic toxicity or hepatic/renal impairment;
• No brainstem metastases and no significant neurological symptoms;
• For subjects with coexisting HBV/HCV infection, hepatic impairment ≤ Grade 1 after prior active antiviral therapy;
• All subjects have provided written informed consent;

You may not qualify if…

• Presence of interstitial pneumonia or infectious fever prior to treatment;
• Comorbid autoimmune diseases or long-term oral corticosteroid use (including those who received oral corticosteroids within 14 days prior to treatment);
• Prior history of thoracic radiotherapy or thoracic surgery;
• Presence of Grade ≥3 hematologic toxicity or hepatic/renal impairment;
• Hypersensitivity to adebrelimab;
• Significant respiratory symptoms that preclude tolerance to radiotherapy;
• Active hepatitis B or C infection, currently on antiviral therapy, and with liver function impairment of Grade 2 or above;
• Presence of pleural effusion or pericardial effusion;

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.